Furthermore, LXs may have a direct antiangiogenic effect in pancreatic cancers by inhibiting vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF-1⍺) release, which are essential for tumor growth and progression [216]. This evidence concerns the gene VEGFA and pancreatic neoplasm.